We have used functional co-reconstitution of purified sarcoplasmic reticulum (SR) Ca 2+ -ATPase (SERCA) with phospholamban (PLB), its inhibitor in the heart, to test the hypothesis that loss-of-function (LOF) PLB mutants (PLB M ) can compete with wild-type PLB (PLB W ) to relieve SERCA inhibition. Co-reconstitution at varying PLB-to-SERCA ratios was conducted using synthetic PLB W , gain-of-function mutant I40A, or LOF mutants S16E (phosphorylation mimic) or L31A. Inhibitory potency was defined as the fractional increase in K Ca , measured from the Ca 2+ -dependence of ATPase activity. At saturating PLB, the inhibitory potency of I40A was about three times that of PLB W , while the potency of each of the LOF PLB M was about one third that of PLB W . However, there was no significant variation in the apparent SERCA affinity for these four PLB variants. When SERCA was co-reconstituted with mixtures of PLB W and LOF PLB M , inhibitory potency was reduced relative to that of PLB W alone. Furthermore, FRET between donor-labeled SERCA and acceptor-labeled PLB W was decreased by both (unlabeled) LOF PLB M . These results show that LOF PLB M can compete both physically and functionally with PLB W , provide a rational explanation for the partial success of S16E-based gene therapy in animal models of heart failure, and establish a powerful platform for designing and testing more effective PLB M targeted for gene therapy of heart failure in humans.
Introduction
Muscle relaxation occurs when the sarcoplasmic reticulum (SR) Ca 2+ -ATPase (SERCA) hydrolyzes ATP and pumps Ca 2+ from the sarcoplasm back into the SR against its concentration gradient. In the heart, SERCA activity is regulated by phospholamban (PLB), a single-span membrane protein that functions to inhibit SERCA by decreasing its apparent Ca 2+ -affinity (increasing K Ca ) [1] . PLB inhibition of SERCA is relieved physiologically either by micromolar Ca 2+ or by phosphorylation of PLB at Ser 16 by PKA [2] [3] [4] , and can also be relieved by a number of point mutations [5] , including S16E (a cytoplasmic domain mutation that partially mimics phosphorylation [6] ) and L31A (a transmembrane domain mutation [5] ). Insufficient SERCA activity is a hallmark of heart failure (HF), which is a leading cause of hospitalization and death in most parts of the world [7] , and overexpression of SERCA, using recombinant AAV vectors, has been shown to relieve heart failure in clinical trials [8] . HF is associated with an increased ratio of PLB to SERCA [9] , so the inhibitory interaction between SERCA and PLB has become an attractive therapeutic target [2] . Indeed, interfering with the SERCA-PLB interaction in HF animal models can result in improved cardiac function [10] [11] [12] [13] [14] . However, complete ablation of PLB can lead to premature death in humans [15] , suggesting that a more subtle approach is needed.
Relief of PLB-dependent SERCA inhibition, whether by micromolar Ca 2+ , PLB phosphorylation, or functional mutation in PLB, has long been thought to require dissociation of the SERCA-PLB complex (Fig. 1A) , a hypothesis supported primarily by cross-linking studies [16, 17] . However, this hypothesis is inconsistent with measurements of fluorescence resonance energy transfer (FRET) from SERCA to PLB that demonstrated no Ca 2+ -dependence of SER-CA-PLB affinity [18] and with intra-PLB FRET and electron paramagnetic resonance (EPR) studies that showed no SERCA-PLB dissociation by either Ca 2+ or phosphorylation of PLB at S16 [19, 20] , suggesting that PLB remains bound upon SERCA activation ( Fig. 1B) . In addition, several loss-of-function (LOF, with less inhibitory potency than WT) PLB mutants have been shown to retain at least some SERCA binding affinity [6, 21, 22] . These results suggest that it might be feasible to identify a LOF PLB mutant (denoted PLB M below) with sufficient SERCA affinity to compete with WT (denoted PLB W below) for SERCA binding, and that such a mutant would be a useful therapeutic reagent. Intriguingly, in vivo cardiac rAAV delivery of a gene corresponding to S16E, a pseudophosphorylated PLB mutant, prevents HF occurrence or progression in small and large animal models [12, 14, 23] . To understand the molecular basis of the therapeutic effectiveness of S16E, we previously studied its structural dynamics, showing that the S16E mutation does not abolish SERCA binding, but it partially unfolds the cytoplasmic domain of PLB (detected by EPR and NMR) [6, 22] , almost as much as is caused by phosphorylation at S16 [20, 22, 24] . We suggest that S16E can relieve SERCA inhibition by competing with PLB W for SERCA binding.
In the present study, we test this hypothesis directly and quantitatively by performing both FRET and functional assays on reconstituted membranes containing donor-labeled SERCA, acceptor-labeled PLB W , and unlabeled S16E. We ask whether this LOF mutant of PLB can compete with the native WT for SERCA binding, which should reduce both FRET and inhibition (Fig. 1C) . We use a similar approach to evaluate the LOF PLB mutant L31A [5] as a phosphorylatable alternative to S16E. The results have important implications for future efforts in gene therapy.
Materials and methods

SERCA purification and labeling
SERCA was purified [25] and labeled with IAEDANS [18] as described previously. To determine the dye concentration in labeled samples, the absorbance (e 334nm = 6100 M À1 cm À1 ) [26] , was measured after treatment with 0.1 M NaOH and 1% SDS. Samples of AE-DANS-SERCA were flash-frozen and stored in the dark at À80°C until further usage.
Synthesis, purification, and labeling of PLB mutants
PLB was assembled on Fmoc-Leu-PEG-PS resin by Fmoc chemistry using a PE Biosystems Pioneer™ peptide synthesis system, as previously reported [18] . The N-terminal amino group of unlabeled PLBs was acetylated using acetic anhydride. For FRET, PLB W was labeled at the N-terminus with the non-fluorescent acceptor Dabcyl-SE (denoted Dab-PLB W ). Peptide composition and concentration were confirmed by MALDI-TOF and amino acid analysis, and samples were stored in methanol at À20°C.
Co-reconstitution of SERCA and PLB
SERCA and PLB were co-reconstituted, as previously described [27] [28] [29] , at 700 lipids/SERCA. Each sample contained 40 lg of SER-CA and varying amounts of PLB to obtain molar ratios of 0-20 PLB to SERCA. Ca 2+ -ATPase activity and FRET measurements were performed immediately after co-reconstitution.
Ca
2+ -ATPase functional measurements
Functional and FRET measurements were carried out at 25°C. ATPase activity was measured using an NADH-detecting enzymelinked assay, as a function of [Ca 2+ ], in 96-well microtiter plates [28, 30] . The time-dependence of absorbance at 340 nm was measured in a SpectraMaxPlus™ microplate reader (Molecular Devices, Sunnyvale, CA). Data were fitted using the Hill function:
where V is the initial ATPase rate and n is the Hill coefficient. The inhibitory effect of each PLB variant was indicated by the observed increase in the apparent Ca 2+ dissociation constant K Ca , measured relative to SERCA reconstituted in the absence of PLB. Based on K Ca measured as above, we define inhibitory potency, P, as the % increase in K Ca (decrease in apparent Ca 2+ affinity) caused by PLB:
where n = PLB/SERCA. To determine the apparent affinity of each PLB variant for SER-CA, P(n) data in Fig. 2B were fitted using the specific binding function:
where K d is the apparent dissociation constant. We assume that the effects of a mixture of PLB W with a LOF PLB M (Fig. 3) on the SERCA K Ca depends on the relative potencies and affinities of the PLB variants competing for a single inhibitory binding site on SERCA:
Fluorescence resonance energy transfer (FRET) measurements
Fluorescence emission spectra were acquired using a Gemini EM microplate fluorimeter (Molecular Devices, Sunnyvale, CA) with excitation at 350 nm from a Xenon flash lamp (1 J/flash). Samples were plated in triplicate (75 lL per well) on 384-well, black wall, optical bottom well plates (Nalge Nunc International, Rochester, NY). Emission spectra were recorded in triplicate, from 
where E max is the limiting value of E for the SERCA-PLB complex at saturation, and [PLB] and K d are in 2-dimensional units, PLB per 1000 lipids [18] . For convenience, titration curves are plotted below with units of PLB/SERCA on the abscissa, but the units are converted to PLB per 1000 lipids to calculate meaningful K d values. In the competition experiments, when AEDANS-SERCA is co-reconstituted with Dab-PLB W and unlabeled PLB M , E depends on the relative affinities of the co-existing PLBs competing for binding to SERCA:
where w, m, A, E are as defined as in Eq. (4). Eq. (6) is simpler than Eq. (4) because PLB M is unlabeled, so E(m) = 0.
Results
Effects of synthetic PLB and its mutants on SERCA K Ca
The effects of synthetic PLB variants on K Ca , the apparent Ca 2+ -affinity of SERCA, were determined in co-reconstituted samples of well-defined lipid/SERCA, and PLB/SERCA. At the approximately physiological level of 5PLB/SERCA [31] , all PLB variants decrease the apparent Ca 2+ affinity of SERCA (K Ca values in Fig. 2A ). This pattern of potency is consistent with previous results using recombinant PLB variants [5, 6, 28, 32, 33] ; I40A inhibits much more than PLB W , while S16E and L31A inhibit much less. While I40A is predominantly monomeric, the other three PLB variants have been shown to be primarily pentameric [5, 34, 35] , so loss of inhibitory function is not due to differences in PLB oligomeric stability.
To further characterize the inhibitory potencies of these PLB mutants, we performed co-reconstitution varying PLB/SERCA from 0 to 20 (maintaining 700 lipids/SERCA), thus probing the normal physiological range (PLB/SERCA 6 5), as well as the pathophysiological range (PLB/SERCA > 5) that is often present in failing myocardium [36, 37] . Potency profiles are given in Fig. 2B , along with fits to Eq. (3). As expected, the saturating potency, P max , of I40A (345 ± 3%) is about 3 times that of PLB W (120 ± 6%) [5, 28, 32] , whereas both LOF PLB M have P max values about 3 times less than that of PLB W (43 ± 7% for S16E, 35 ± 10% for L31A). Surprisingly, the apparent affinities of PLB W and I40A for SERCA obtained from fitting their potency profiles in Fig. 2B are not significantly different: K d values (PLB/1000 lipids) are 4.1 ± 0.8 (PLB W ), 4.0 ± 0.4 (I40A), 5.1 ± 1.1 (S16E), and 9.1 ± 4.9 (L31A). We conclude that the differences in potency displayed by these PLB variants reflect mainly the intrinsic potency of the SERCA-PLB complex at saturation, P max , not the binding affinity, 1/K d (Eq. (3)).
Functional competition between PLB W and LOF PLB M
To determine whether LOF PLB M can attenuate the inhibition of SERCA induced by PLB W , we co-reconstituted SERCA with mixtures of PLB W and each of the LOF PLB M (S16E and L31A). In Fig. 3 , triangles illustrate the measured potencies of SERCA/PLB W /PLB M mixtures at 1/2/2, 1/2/5, 1/5/5, and 1/5/10. Functional competition data are displayed relative to the inhibition profile of PLB W from Fig. 2B (as upper bound, Fig. 3 dashed line) and an average of LOF PLB M profiles from Fig. 2B (as lower bound, Fig. 3 dotted line) . For each sample containing w PLB W and m PLB M mixtures, the increase in K Ca is significantly smaller than for the corresponding reference samples containing only w PLB W . This is the relevant effect for gene therapy applications. These experimental data, reflecting (B) Dependence of PLB inhibitory potency (P, Eq. (2)) on PLB/SERCA, along with fits to the data using Eq. (3), with best-fit P max (%) and K d (PLB/1000 lipids) values in inset table.
Each plotted symbol represents mean ± SEM from at least three measurements. 2B ). Solid curves represent fits to the competition data using Eq. (4). Each plotted point is the mean ± SEM from at least three measurements.
the functional competition of PLB M with PLB W for SERCA binding (Fig. 3 symbols) , were fitted using Eq. (4), yielding apparent K d values (PLB M /1000 lipid) of 3.2 ± 0.5 for S16E and 3.5 ± 0.6 for L31A. These are similar to the K d values measured directly from the functional potency profiles of these PLB M (Fig. 2B , Eq. (3)).
FRET measurement of competition between PLB W and LOF PLB M
We measured FRET between AEDANS-SERCA and Dab-PLB W coreconstituted in lipid over a range of PLB/SERCA. Lipids/SERCA was fixed at 700. The resulting FRET profile (Fig. 4, circles) allows a direct determination of PLB's binding affinity for SERCA, as previously shown [18] . The dashed line represents the best fit to Eq. (5), giving K d = 1.2 ± 0.3 PLB/1000 lipids. This affinity is significantly tighter than indicated by the functional profile (Fig. 2B , PLB W ), suggesting that some binding occurs without inhibition. To determine whether PLB M and PLB W physically compete for SER-CA binding, we co-reconstituted AEDANS-SERCA, Dabcyl-PLB W , and unlabeled LOF PLB M at SERCA/PLB W /PLB M = 1/2/m (m = 2, 4, 8). As in the case of functional competition, FRET is decreased by both PLB M (Fig. 4 , triangles are below circles), indicating competition with PLB W for binding to SERCA. Thus, both unlabeled LOF mutants PLB M compete physically with labeled PLB W (Fig. 4) . These FRET competition data were fitted using Eq. (6), yielding K d values (PLB/1000 lipids) for the two PLB M binding to SERCA that were indistinguishable: 1.8 ± 0.5 for S16E and 2.2 ± 0.8 for L31A.
Discussion
By varying the molar ratio of PLB to SERCA and measuring the Ca 2+ -dependence of SERCA activity, we found that the potency profiles, P(n), of all four PLB variants are characterized by indistinguishable affinities (1/K d ), despite saturating potencies (P max ) that vary by a factor of 10 (I40A ) PLB W > S16E > L31A) (Fig. 2B) . We conclude that, for these PLB variants, the inhibition in the SER-CA-PLB complex at saturation (P max ) is essentially independent of affinity. This result suggests that the two LOF PLB M should compete effectively with PLB W for SERCA binding, thus relieving SERCA inhibition. The functional competition data (Fig. 3 ) supports this hypothesis-both S16E and L31A compete effectively with PLB W to decrease the net potency (shift in K Ca ). Indeed, the K d values of S16E and L31A calculated from the functional competition measurements (3.2 ± 0.5 for S16E and 3.5 ± 0.6 from L31A, Fig. 3 ) are even slightly smaller (greater affinity) than calculated from the potency profiles (5.1 ± 1.1 for S16E and 9.1 ± 4.9 for L31A, Fig. 2B ).
The similar SERCA affinity of PLB W and LOF PLB M is further supported by the FRET data, which demonstrate physical competition between these PLB variants (Fig. 4 ). These results demonstrate that inhibitory potency of PLB M is distinct from binding affinity and thus provide a rational explanation for the partial success of S16E-based gene therapy in animal models of heart failure [12, 14, 23] . This work establishes a convenient, rapid FRET-based method for testing improved PLB M candidates for HF therapies. Indeed, the L31A mutant may already be superior to S16E as a therapeutic candidate, because it can be phosphorylated by PKA at Ser 16, thus providing a level of adrenergic response that S16E lacks. Although the current collection of PLB variants does not show significant variation in K d , the observation that P max is uncoupled from K d supports the hypothesis that more LOF PLBs can be designed that have either (a) a lower P max than S16E or L31A, without decreasing affinity, or (b) a higher affinity without increasing P max . Indeed, previous studies with PLB mutants show that insight into structure-function correlations, gained from EPR and NMR analysis of PLB structural dynamics and function, can be used effectively to guide the PLB M engineering process [6, 22] . 
